贝鲁莫司地减少口腔慢性移植物抗宿主病组织炎症与纤维化:ROCKstar伴随研究
这项ROCKstar 2期试验的伴随研究评估了20例口腔慢性移植物抗宿主病(cGVHD)患者接受贝鲁莫司地治疗6个月前后口腔黏膜、小唾液腺、皮肤及外周血的免疫动态。治疗后口腔黏膜胶原减少,口腔黏膜(14对)和小唾液腺(11对)中IL-17+细胞频率下降,口腔黏膜免疫细胞频率降低,小唾液腺和外周血CD4调节性T细胞增加。唾液TGF-β1显著下降且与IL-17水平强相关。
要点
- 贝鲁莫司地治疗6个月后口腔黏膜胶原减少,IL-17+细胞频率在口腔黏膜和小唾液腺下降。
- 口腔组织中IL-17主要由非T细胞产生,治疗后口腔黏膜免疫细胞频率降低。
- 小唾液腺和外周血CD4调节性T细胞增加,唾液TGF-β1显著下降且与IL-17强相关。
核心结论
- 贝鲁莫司地治疗可减少cGVHD组织纤维化和炎症,提示ROCK2抑制在缓解cGVHD方面具有治疗作用。
研究设计与样本
- ROCKstar 2期试验的伴随研究,纳入20例口腔cGVHD患者,评估贝鲁莫司地治疗6个月前后口腔黏膜、小唾液腺、皮肤及外周血的免疫动态。
主要发现
- 贝鲁莫司地治疗后口腔黏膜胶原减少,口腔黏膜(n=14对)和小唾液腺(n=11对)中IL-17+细胞频率下降。
- 口腔组织中IL-17主要由非T细胞产生,治疗后口腔黏膜免疫细胞频率降低,而小唾液腺和外周血中CD4调节性T细胞增加。
- 按总体或口腔特异性临床应答标准,应答者口腔黏膜I型胶原和IL-17减少。
- 唾液TGF-β1显著下降,且TGF-β1与IL-17水平呈强相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Belumosudil (KD025), an oral, selective, Rho-associated, coiled-coil-containing protein kinase 2 (ROCK2) inhibitor, is approved for third-line treatment of chronic graft-versus-host disease (cGVHD). Previous studies demonstrated that ROCK2 inhibition reduces blood interleukin-17 (IL-17) activity and promotes regulatory T-cell (Treg cell) recovery. However, these studies did not evaluate immune responses within cGVHD-affected tissues. This study assessed tissue-level immune dynamics in 20 patients with oral cGVHD from the phase 2 ROCKstar trial, before and after 6 months of belumosudil treatment, focusing on key effector sites (oral mucosa [OM], minor salivary glands [MSGs], and skin) and the peripheral blood. After belumosudil treatment, reduction in collagen was observed in OM in parallel with decreased IL-17+ cell frequency in both OM (n = 14 pairs) and MSG (n = 11 pairs). IL-17 was primarily produced by non-T cells in the oral tissues. Immune cell frequencies in the OM decreased after treatment, whereas CD4 Treg cells increased in both the MSG and blood. Per overall or mouth-specific clinical response criteria, responders to belumosudil exhibited a reduction in collagen type I and IL-17 in the OM. Additionally, salivary transforming growth factor β1 (TGF-β1), a critical driver of fibrosis, decreased significantly, with a strong correlation observed between TGF-β1 and IL-17 levels. These findings illustrate the tissue-level response to belumosudil therapy and suggest that there is a reduction in tissue fibrosis and inflammation, thereby highlighting the therapeutic impact of ROCK2 inhibition in mitigating cGVHD. The ROCKstar study was registered at www.ClinicalTrials.gov as #NCT03640481.
引用
- Sharma R, Holtzman NG, Pusic I, et al. Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study. Blood Adv. 2025. PMID: 40311075. doi:10.1182/bloodadvances.2025016170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。